Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Transcript
Veru Inc. reported a $23.4 million public offering that lifted cash and working capital to $33 million and $29.7 million respectively, while narrowing its quarterly net loss to $5.3 million ($0.26 per share). The company received FDA feedback confirming two regulatory pathways for its Novosarm‑GLP‑1 combination—either ≥5% incremental weight loss or a functional benefit with comparable weight loss. Veru also highlighted the FDA’s acceptance of total‑hip bone mineral density as a surrogate endpoint, expanding potential indications for Novosarm in obesity and osteoporosis. The Phase 2b PLATO study, enrolling about 200 patients aged 65+ with obesity, is slated to start this quarter with an interim analysis in 2027.
Structures of Marburgvirus Glycoprotein and Its Complex with NPC1 Receptor
Researchers solved cryo‑EM structures of Marburgvirus (RAVV) glycoprotein (GP) in three states—unbound, bound to human NPC1‑C, and bound to a neutralizing nanobody. The structures reveal a flexible glycan‑cap loop that partially blocks the receptor‑binding site and a distinct NPC1 binding...
Kamada Ltd (KMDA) Q4 2025 Earnings Call Transcript
Kamada reported Q3 2025 revenue of $47 million, a 13% year‑over‑year increase, and adjusted EBITDA of $11.7 million, up 34% from the prior year. The company reaffirmed its full‑year revenue target of $178‑$182 million and adjusted EBITDA guidance of $40‑$44 million, citing strong performance...
Multidimensional Profiling of Heterogeneity in Supratentorial Ependymomas
A multinational team integrated single‑cell and single‑nucleus RNA sequencing, 10x Xenium spatial transcriptomics, and live‑cell imaging to map heterogeneity in supratentorial ependymomas (ST‑EPN). The study profiled 42 tumors across all molecular subgroups, uncovering eight recurrent transcriptional metaprograms that align with distinct...
Capturing Dynamic Phage–Pathogen Coevolution by Clinical Surveillance
A high‑resolution clinical surveillance program in Bangladesh identified a novel phage‑inducible chromosomal island‑like element, PLE11, that rapidly spread through Vibrio cholerae populations, reaching 91% prevalence within nine months. PLE11 conferred resistance to the dominant lytic phage ICP1 despite the phage’s...
Viant Technology Inc (DSP) Q4 2025 Earnings Call Transcript
Vanda Pharmaceuticals reported 2025 revenue of $216.1 million, up 9% year‑over‑year, driven primarily by Fanapt’s 24% sales increase and a successful bipolar launch. The company secured FDA approval for tradipitant (Nirius) to prevent motion‑sickness vomiting, with a commercial rollout slated for...
Using Mosquitoes to Vaccinate Bats Could Curb the Spread of Deadly Diseases
Scientists have engineered Aedes aegypti mosquitoes to carry oral vaccines for rabies and Nipah virus, allowing the insects to inoculate bats through feeding or saline drinking stations. Laboratory trials showed that vaccinated bats and mice generated neutralising antibodies and survived...
New Psychedelic Fungus Rewrites Origins of Magic Mushrooms
Researchers have described a new African psychedelic mushroom, Psilocybe ochraceocentrata, that closely resembles the well‑known Psilocybe cubensis. Genetic analysis shows the two share a common ancestor about 1.5 million years ago, overturning the long‑held belief that cattle introduced P. cubensis to the...
FDA Leucovorin Approval Raises Concerns About Reliance On Case Reports
The FDA granted approval for leucovorin calcium tablets to treat a rare genetic disorder that impairs folate transport to the brain. Unlike typical approvals, the agency relied primarily on a handful of patient case reports rather than a sponsor‑run clinical...
Biologics and Biosimilars Landscape 2025: IP, Policy, and Market Developments
The FDA approved 18 biosimilars in 2025, spanning six therapeutic areas and marking a surge in interchangeable designations to over 20. A wave of denosumab biosimilars and first‑in‑kind interchangeable products such as Poherdy® and Omlyclo® highlighted market diversification. BPCIA litigation...
Study Suggests Long Non-Coding RNA Has Potential as New Class of Genetic Medicine
Researchers at the University of Toronto have engineered synthetic long non‑coding RNA (lncRNA) molecules that can dampen inflammatory responses. The study, led by PhD student Janice Pang and biologist Omar Khan, demonstrates that these engineered lncRNAs reduce cytokine release in...
Ochsner MD Anderson Leads the Southern U.S. in Offering Precision Cancer Radiation Treatment
Ochsner Health and the MD Anderson Cancer Center have launched a joint precision radiation oncology program in New Orleans, marking the first Southern U.S. facility to offer MR‑guided adaptive radiotherapy. The center leverages AI‑driven treatment planning and real‑time imaging to...
Protara Therapeutics, Inc. (TARA) Reports Narrower Loss for Q4
Protara Therapeutics reported a Q4 2025 loss of $0.37 per share, an improvement from the $0.48 loss a year earlier. The narrowing loss reflects higher clinical development spending as the company advances its lead cell‑therapy candidate, TARA-002, into Phase II...
CDMO Neuland Labs Expects Commercial Production Facility to Be Operational by Summer
Neuland Laboratories announced that the first module of its new commercial peptide manufacturing facility will be operational by summer on its 17‑acre Bonthapally campus in India. The module adds 6,370 L of solid‑phase and liquid‑phase peptide synthesis capacity, ranging from 250 L...
Procalcitonin Vs. C-Reactive Protein in Neonatal Sepsis
Researchers published a comparative study in Pediatric Research showing that procalcitonin (PCT) rises within 6‑12 hours of infection in very low birth weight infants, while C‑reactive protein (CRP) peaks later at 24‑48 hours. The data reveal that PCT offers higher...
AI-Enabled Quantum Refinement Cracks the Code of Difficult-to-Map Proteins
A new tool called AI‑enabled Quantum Refinement (AQuaRef) merges quantum‑mechanical calculations with machine‑learning to refine protein structures. Developed by Lawrence Berkeley National Lab and Carnegie Mellon, it is integrated into the Phenix software suite used worldwide. In tests on 71...
Lundbeck CEO Talks Drug Pricing, Protecting Biotech and European Needs
Lundbeck chief executive Charl van Zyl warned that Europe’s fragmented drug‑pricing regime threatens biotech sustainability and patient access. He cited recent remarks by HHS Secretary Robert F. Kennedy Jr. suggesting Europeans already pay higher prices than Americans. Van Zyl called...
FDA Clears New Formulation of Lantheus' PSMA Imaging Agent
The FDA has cleared Pylarify TruVu, a reformulated version of Lantheus’ PSMA‑targeting radiopharmaceutical piflufolastat F‑18. The new formulation improves stability at higher radioactive concentrations, enabling larger batch production and broader distribution. Lantheus plans a Q4 2026 commercial launch with a rolling geographic...
Phase III Data Support Johnson & Johson’s Teclistamab as Second-Line Therapy for RRMM
Johnson & Johnson has filed a Type II variation with the European Medicines Agency to add teclistamab, a bispecific T‑cell‑redirecting antibody, as a second‑line monotherapy for relapsed/refractory multiple myeloma. The Phase III MajesTEC‑9 trial, enrolling 614 patients, demonstrated a 71 % reduction in...
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings
Tenax Therapeutics Inc. posted a Q4 2025 net loss of $0.38 per share, reflecting continued investment in its clinical-stage pipeline. The company’s cardiopulmonary portfolio includes TNX-101, TNX-102 and TNX-103, which have all cleared Phase II trials for pulmonary hypertension in...
Australian Plastics Recycling Company Targets Critical Minerals
Australian startup Samsara Eco, which uses AI‑designed enzymes to break down plastics into reusable monomers, is raising more than $70 million to apply the technology to extract critical minerals from electronic waste. The company, backed by Temasek, Hitachi’s VC arm and...
Regulatory Pharmaceutical Fellowship Program
Several U.S. universities have launched two‑year medication safety fellowships that rotate participants through academic training, a major pharmaceutical company, and the FDA. Butler University offers two tracks with Regeneron and Eli Lilly, Purdue partners with AbbVie, and Rutgers collaborates with Pfizer....
Peptides in the Pipeline: How Companies Are Overcoming the Early-Stage Challenges
Peptide therapeutics are booming, with more than 2,000 candidates in discovery and pre‑clinical stages and projected global sales of $91.4 bn by 2025. Companies like Orocidin faced severe synthesis and purification hurdles for their QR‑01 peptide, but Syngene’s custom low‑loading resin...
Johns Hopkins Leads $24M Multinational Consortium to Find Hepatitis B Cure
Johns Hopkins Medicine is heading a five‑year, $24 million NIH‑funded Hepatitis B and HIV Cure Consortium that brings together research teams from the United States, Brazil, India, Senegal and Uganda. The first year will enroll 450 participants co‑infected with HIV and chronic...
Efgartigimod Effective in Treating Juvenile Myasthenia Gravis
A multicenter retrospective study of 17 Chinese patients with juvenile myasthenia gravis found that weekly efgartigimod 10 mg/kg for four weeks produced rapid and substantial clinical improvement. Clinically meaningful improvement was observed in 70.6% of patients by week 1 and 91.7% by...
BioNTech Co-Founders Launch New mRNA Company
BioNTech announced it will create an independent biotech company dedicated to next‑generation mRNA technologies. The spin‑out will be led by co‑founders Ugur Sahin and Özlem Türeci, who will assume management by the end of 2026. BioNTech will contribute core mRNA assets in...
CSL Breaks Ground on $1.5B Illinois Immunoglobulin Plant Expansion
CSL‑Behring broke ground on a $1.5 billion expansion of its Kankakee, Illinois manufacturing complex, slated to be operational by 2031. The project will add at least 300 pharmaceutical positions and roughly 800 construction jobs, with the state offering more than $200 million...
Antibiotic Resistance Can Vary Depending on Where the Bacteria Live
Researchers at the Technical University of Denmark discovered that antibiotic resistance measurements can shift dramatically when test conditions change. Standard laboratory assays use fixed, uniform environments, but altering factors such as growth medium or temperature can make the same bacterium...
ARPA-H Launches Program to Develop Biosensors that Can Track Multiple Signals
The Advanced Research Projects Agency for Health (ARPA‑H) has launched the Delphi program to develop modular biosensors that can monitor multiple physiological signals such as inflammation markers, hormones, and drug levels. The initiative relies on electronic "chiplet" technology, allowing developers...
ARPA-H Launches Program to Develop Biosensors that Can Track Multiple Signals
The Advanced Research Projects Agency for Health (ARPA‑H) has unveiled the Delphi program to create modular biosensors that can monitor multiple biomarkers such as inflammation markers, hormones, and drug levels. The initiative relies on electronic "chiplet" technology, allowing developers to...
A Dose of Psilocybin Helps Smokers Quit in New Study
Researchers at Johns Hopkins found a single dose of psilocybin dramatically increased smoking cessation rates compared with nicotine patches. In a randomized trial of 82 smokers, 17 of 41 participants who received psilocybin remained abstinent after six months versus four...
First-of-Its-Kind Vaccine Protects Children From Deadly E. Coli Infections
Scientists announced ETVAX, the first oral vaccine that targets enterotoxigenic *E. coli* (ETEC) in children, after a large‑scale trial in The Gambia. The study involved 4,936 infants aged six to 18 months and demonstrated a 48% reduction in moderate‑to‑severe ETEC...
STAT+: Novo Nordisk Is Warned by the FDA for Failing to Report Side Effects Tied to GLP-1 Drugs
Novo Nordisk received an FDA warning letter on March 5, 2026 for failing to report suspected side effects of its GLP‑1 medicines. The violations were uncovered during a 2025 inspection of the company’s facilities and were described as “serious.” The agency warned...
Building for Decades: Dubai’s Long Game in Life Sciences
Dubai is positioning itself as a long‑term hub for healthcare and life sciences through two complementary free‑zone clusters – Dubai Healthcare City (DHCC) and Dubai Science Park (DSP). DHCC is undergoing a $1.3 bn expansion that will create six tightly linked...
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
The FDA has defined the scope of pre‑submission facility meetings to curb manufacturing‑related complete response letters that delay drug approvals. It agreed to cover prior production‑site inspections, novel process elements and supply‑chain node strategies, while rejecting topics such as alternative...
Desert to Discovery: Five Hot Biotechs in Arizona
Arizona's biotech sector is booming, with $3.7 billion invested over the past seven years and a growing pipeline of innovative companies. Nectero Therapeutics secured a $96 million Series D to develop a fast‑track, breakthrough‑designated endovascular treatment for abdominal aortic aneurysms, while Humabiologics obtained...
Researchers Track Mineral Growth on Bioorganic Coatings in Real Time at Nanoscale
Researchers at Jeonbuk National University used a quartz crystal microbalance to compare calcium‑phosphate mineralization on titanium dioxide nanoparticles coated with polydopamine (PDA) versus zein. Real‑time measurements showed PDA‑coated particles accumulated 7,780 ng of mineral, roughly 37% more than the 5,641 ng recorded...
STAT+: Pharmalittle: We’re Reading About a U.S. Senator Probing FDA, BioNTech Founders Leaving, and Much More
BioNTech co‑founders Ugur Sahin and Özlem Türeci will leave the company by year‑end to launch an unnamed mRNA‑focused venture, with BioNTech retaining a minority stake and licensing key technology. The split allows BioNTech to concentrate on its late‑stage cancer pipeline...
China Is Going After the World's Most Expensive Drugs: Endpoints Signal
China is actively targeting ultra‑expensive gene therapies, challenging the notion that these treatments are immune to price competition. Recent regulatory approvals and centralized procurement initiatives have forced manufacturers to negotiate steep discounts on therapies that once commanded multi‑million‑dollar price tags....
FDA Widens Use of Leucovorin without New Trial Data
The U.S. Food and Drug Administration has approved the generic form of leucovorin, also known as folinic acid, for treating cerebral folate deficiency (CFD). The decision widens the drug’s label despite the absence of new clinical trial data, relying on...
Cell and Gene Therapy Manufacturing Market to Skyrocket to $146B by 2032
Credence Research forecasts the global cell and gene therapy manufacturing market to surge from $19.3 billion in 2024 to $146.2 billion by 2032. The compound annual growth rate is estimated at 28.8%, propelled by rising demand for advanced therapies, expanding commercialization, and...
AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs
Breakout Ventures announced the close of its third fund, raising $114 million to back AI‑driven biotech startups. The capital will be deployed to early‑stage companies, including a University of Chicago spin‑out focused on computational small‑molecule design and a stealth venture tackling...
Statement on Biomedical Countermeasures Initiative
BIOTECanada welcomes the launch of the National Research Council of Canada’s Biomedical Countermeasures Initiative, a key component of the federal Defence Industrial Strategy. The program is designed to strengthen Canada’s domestic capacity to develop and manufacture diagnostics, vaccines, and therapeutics...
Rising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
Stylus Medicine entered the cell‑therapy arena in May 2025 with an in‑vivo CAR‑T platform that delivers a lipid nanoparticle‑encapsulated recombinase to engineer T cells inside patients. The move comes after major pharma acquisitions—BMS buying Orbital Therapeutics for $1.5 billion and Gilead...
Samsung Biologics, Eli Lilly to Establish Biotech Incubator in Incheon
Samsung Biologics and U.S. pharma leader Eli Lilly have signed an agreement to launch a biotech incubator in Incheon’s Songdo district. The facility will host Lilly’s Gateway Labs platform, offering lab space, equipment, funding and R&D collaboration to emerging biotech firms....
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
Dyne Therapeutics reported that its exon‑skipping candidate z‑rostudirsen sustained respiratory and cardiac benefits through 24 months in the Phase 1/2 DELIVER study for Duchenne muscular dystrophy. The therapy maintained forced vital capacity, circumferential strain and left‑ventricular ejection fraction improvements compared with...
Junshi Receives China’s NMPA Acceptance for Toripalimab Injection
Junshi Biosciences has received acceptance from China’s National Medical Products Administration for its subcutaneous toripalimab injection (JS001sc), covering 12 cancer indications. The filing marks the first domestic anti‑PD‑1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage....
Ascletis Announces Positive Topline Results From U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule...
Ascletis Pharma reported positive topline data from a U.S. Phase II, 24‑week study of its ultra‑long‑acting subcutaneous depot GLP‑1R agonist ASC30. The once‑monthly formulation A1 produced a placebo‑adjusted mean weight loss of 7.5% at week 16 and sustained a 5.8%...
BioNTech Co-Founders to Exit Company and Start a New One
Uğur Şahin and Özlem Türeci announced they will leave BioNTech by the end of 2026 to launch a new company focused on next‑generation mRNA technologies. BioNTech will concurrently narrow its portfolio, concentrating on late‑stage therapeutic candidates and its existing vaccine...
STAT+: Large Drugmakers Are Developing Fewer Antibiotics, Analysis Finds
A new analysis shows the world’s largest pharmaceutical firms cut antimicrobial development by 35% over the past five years, dropping from 92 to 60 candidates. Only five of the 39 pipeline projects aimed at WHO priority pathogens include pediatric formulations...